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Abstract
Myotonic dystrophy type 1 (DM1) is a multi-systemic disorder caused by a CTG trinucleotide repeat expansion (CTG
exp)i n
the DMPK gene. In skeletal muscle, nuclear sequestration of the alternative splicing factor muscleblind-like 1 (MBNL1)
explains the majority of the alternative splicing defects observed in the HSA
LR transgenic mouse model which expresses a
pathogenic range CTG
exp. In the present study, we addressed the possibility that MBNL1 sequestration by CUG
exp RNA also
contributes to splicing defects in the mammalian brain. We examined RNA from the brains of homozygous Mbnl1
DE3/DE3
knockout mice using splicing-sensitive microarrays. We used RT-PCR to validate a subset of alternative cassette exons
identified by microarray analysis with brain tissues from Mbnl1
DE3/DE3 knockout mice and post-mortem DM1 patients.
Surprisingly, splicing-sensitive microarray analysis of Mbnl1
DE3/DE3 brains yielded only 14 candidates for mis-spliced exons.
While we confirmed that several of these splicing events are perturbed in both Mbnl1 knockout and DM1 brains, the extent
of splicing mis-regulation in the mouse model was significantly less than observed in DM1. Additionally, several alternative
exons, including Grin1 exon 4, App exon 7 and Mapt exons 3 and 9, which have previously been reported to be aberrantly
spliced in human DM1 brain, were spliced normally in the Mbnl1 knockout brain. The sequestration of MBNL1 by CUG
exp
RNA results in some of the aberrant splicing events in the DM1 brain. However, we conclude that other factors, possibly
other MBNL proteins, likely contribute to splicing mis-regulation in the DM1 brain.
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Introduction
Myotonic dystrophy type1 (DM1) is a multi-systemic disorder
affecting skeletal muscle, heart, ocular lens, testis, and the central
nervous system (CNS). CNS involvement in adult-onset DM1 includes
visual spatial and attention deficits, dysexecutive syndrome, apathy,
avoidant behavior and excessive daytime sleepiness (review [1]).
Although neuropathological studies have revealed several morpholog-
ical changes [2,3,4], whether these changes contribute to the clinical
symptoms observed in DM1 remains to be determined.
DM1 is caused by the unstable expansion of CTG trinucleotide
repeats in the 39 untranslated region of the DM protein kinase
(DMPK) gene [5]. Recent evidence suggests that transcripts
containing expanded CUG repeats (CUG
exp) accumulate in
nuclear RNA foci and exert toxic effects on a variety of cellular
regulatory pathways including splicing and transcription [6]. One
disease model that is supported by considerable experimental
evidence proposes that CUG
exp RNAs cause sequestration and
inhibition of the RNA-binding protein MBNL1 [7]. In support of
this model, Mbnl1 knockout mice develop the muscle, eye, and
RNA splicing abnormalities that are characteristic of DM1 disease
[8]. In addition, we have reported a strong correlation in skeletal
muscle splicing changes between two mouse models of DM1, the
HSA
LR transgenic and the Mbnl1 knockout [9].
In the CNS of DM1 patients, mutant DMPK transcripts
accumulate in neuronal nuclei and sequester MBNL1 and
MBNL2 [10]. Although abnormal regulation of several alterna-
tively spliced exons has also been documented in the DM1 brain
[10,11,12,13], it is not clear if MBNL1 sequestration contributes to
aberrant splicing. Here we used splicing-sensitive microarrays to
detect mis-splicing in the Mbnl1
DE3/DE3 knockout brain.
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Splicing perturbations in the Mbnl1
DE3/DE3 knockout
brain
To test directly whether loss of MBNL1 expression contributes
to aberrant splicing in the CNS, RNA was extracted from the
brains of age-matched males carrying homozygous Mbnl1
DE3/DE3
knockout or wild-type alleles in the same (C57BL/6J) background
and analyzed on splicing-sensitive microarrays [9]. Experience
with this method indicates that differences in the log2 of the ratio
of exon skipping to inclusion (the skip/include ratio) between two
samples (sepscore) with an absolute value .0.3 can be validated by
RT-PCR. We observed 14 events in Mbnl1
DE3/DE3 knockout mice
that exceeded this score (Table S1). We used RT-PCR to validate
a subset of alternative cassette exons identified by microarray
analysis and found four events (Sorbs1 exons 6 and 25, Spag9 exon
31, Dclk1 exon 19) that showed significant differences in splicing
between wild-type and knockout mice in both the hippocampus
and cerebellum (Figure 1A,B). Sorbs1 is particularly interesting
because it is expressed in multiple tissues and exon 25 is regulated
during postnatal development [9,14]. In heart, MBNL1 is a major
factor which regulates exon 25 splicing with nearly complete
inclusion in wild-type adult heart but only ,60% inclusion in the
Mbnl1 knockout heart. While this exon is also mis-spliced in the
Mbnl1 knockout brain, the effect of MBNL1 loss on this exon is
considerably less in both the hippocampus and cerebellum. This
modest effect of MBNL1 loss on other mis-regulated exons was
also apparent for Spag9 exon 31, Sorbs1 exon 6 and Dclk1 exon 19
(Figure 1B). Nevertheless, these exons are regulated during
developmental transition from neonatal (P6) to adult (P42)
forebrain (Figure 1A), which indicates other factor may play a
role in splicing regulation during this period.
Splicing microarrays also revealed mis-splicing of Camk2d,s ow e
further investigated splicing of this gene. Importantly, Camk2d
splicing is regulated during postnatal development with the major
isoforms all containing exons 14a and 17 with alternative splicing
of the exon 14b, 15 and 16 cassettes to generate several major
isoforms, including d1, d2, d3, d3.1, d4 and d9 (Figure 2). Previous
reports have indicated that the d1 isoform is the major splice
variant in the adult rat forebrain, while d4 isoform is expressed in
the neonatal rat forebrain [15]. We observed that in P1 whole
brain, P6 fore- and hindbrain, d1 and d9 are the major isoforms
while in adults (P42), exon 15 is preferentially spliced, so that in
addition to d1, d4 is also the major form in forebrain and both d4
and d3 are expressed in hindbrain. In accordance with other
splicing changes where immature splicing isoforms are expressed
in the adult tissues, splicing of the fetal d9 isoform significantly
increased in the hippocampus of Mbnl1 knockouts compared to
controls although the increase was modest and was not observed in
the cerebellum. While the d9 isoform increased, the d3( +14b 215
216) isoform decreased in Mbnl1 knockout mouse hippocampus
compared with wild-type.
Aberrant splicing in human brain samples and
comparison with Mbnl1 knockout brain
To determine whether these mis-splicing events predicted from
the Mbnl1 knockout brain microarray data were also observed in
the human DM1 brain, we aligned affected mouse exons to the
human genome and found 12 exons that are conserved and
orthologous to MBNL1-dependent mouse exons (Table S2). We
examined all of these events in post-mortem human temporal
cortex and cerebellum. The most striking result in human DM1
brain was mis-splicing of SORBS1 exon 26 (orthologous to mouse
exon 25). In the temporal cortex, the average percentage of exon
26 inclusion in DM1 was ,40% while those observed in the
normal controls and in the disease controls were ,85% and
,90%, respectively (Figure 3A and B, upper). In the cerebellum,
exon 26 inclusion was also significantly decreased in DM1
compared with in disease controls, although this difference is
subtler than that in the temporal cortex. Both DCLK1 exon 19
inclusion and MPRIP exon 9 inclusion were significantly decreased
in DM1 temporal cortex (Figure 3A and B, middle and bottom),
whereas there is no difference in these splicing events between
DM1 and disease cerebellums.
In humans, the splicing of CAMK2D is also regulated in a tissue-
specific and developmental manner. We found that d9 was
expressed almost exclusively in human fetal whole brain (unlike
rodent brain), while d1 was predominantly expressed in adult
human temporal cortex samples (Figure 3C to E). In contrast, the
percentage of the d9 isoform was significantly increased in adult
DM1 temporal cortex compared to both disease and normal
controls. This increase was ,30% in DM1 temporal cortex
(Figure 3E), or apparently larger than that observed in the
hippocampus of Mbnl1 knockout mice (Figure 2), although we
could not conclude which of the following changes will have a
stronger impact: (a) an increase from 0 to ,2.5% in Mbnl1
knockout mice (Figure 2C), or (b) an increase from ,10% to
,30% in DM1 temporal cortex (Figure 3E). As a result of the
increase of d9, the percentage of d1 was significantly decreased in
the DM1 temporal cortex. In DM1 and disease control
cerebellums, d9 was a major isoform and there is no difference
between these two. Unlike mouse cerebellum, d3 isoform was not
observed in any groups of human brains.
Initially we did temporal lobe autopsy on human since a former
report showed splicing defects of several exons in this region [10].
We did hippocampus analysis on mouse because it is a key region
of the brain involved in learning and memory. We thought a
concern of regional difference between hippocampus and
temporal lobe may not be an issue since a report showed similar
tau pathology in hippocampus and temporal cortex [4] and we
have compared the splicing pattern of each exon in these regions
of mouse brain and found similar splicing defects of Sorbs1 exon 25
and Camk2d exon 14–16 (increased expression of d9) in Mbnl1
knockout mice (Figure S1). We also used cerebellum samples as a
reference region since no apparent cerebellar symptoms in DM1
patients and the lack of RNA foci in DM1 cerebellar cortex have
been reported [10]. Although we did not show a direct binding of
MBNL1 on these RNA by CLIP (cross linked immuno
precipitation), we identified several YGCY motifs in the upstream
and downstream introns of these alternative spliced cassettes
(Table S3).
We determined by Southern blot analysis the CTG repeat
number of the same brain tissues from which we took RNA for
RT-PCR (Table 1). Cerebral cortex showed greater CTG repeat
number and larger intra-tissue CTG length heterogeneities than
cerebellum, consistent with a previous observation [16]. The
comparison between the degree of aberrant splicing of each exon
and each shortest, median and longest CTG repeat number
showed no correlation (Figure S2). Several splicing defects have
been reported in DM1 brain and we confirmed some of them
(exon 4 of GRIN1, exons 3 and 12 of MAPT and exon 9 of APP)i n
our human DM1 temporal cortex samples (Figure S3A).
However, our splicing microarray analysis did not detect any
mis-splicing of these exons in the Mbnl1 knockout model. RT-
PCR using each set of specific primer for these exons (Grin1 exon
4, Mapt exons 3 and 9, and App exon 7) also revealed no defects of
splicing (Figure S3B).
Novel Splicing Defects in Mbnl1 KO and DM1 Brain
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In the present study, we found three novel splicing events, Sorbs1
exon 25 (exon 26 in human), Dclk1 exon 19, and Camk2d exon 14–
16 (exon 14–15 in human), altered both in DM1 and in Mbnl1
knockout brains. This is the first report of mis-splicing of
orthologous exons in brain tissues from human DM1 and Mbnl1
knockout mice, although mis-splicing of exons 3 and 12 (9 in mice)
of MAPT has been shown in human DM1 brain [10,13] and in the
CTG transgenic mouse brain [17]. In general, the Mbnl1 knockout
hippocampus and DM1 temporal cortex shared similar splicing
defects. We also confirmed similar splicing defects of some genes in
the hippocampus and temporal cortex of Mbnl1 knockout mice
(Figure S1). The expression of the fetal splicing isoforms in our
samples is consistent with other splicing abnormalities in which
fetal splice isoforms are expressed in adult DM1 patients and
model mice. Interestingly, only the increase in GRIN1 exon 4
inclusion in DM1 brain does not represent a return to a fetal
splicing profile (Figure S3), which may suggest that distinct splicing
factors regulate this splicing event. Our data did not demonstrate
directly that MBNL1 regulates the splicing of these exons.
However, we found many YGCY motifs that could potentially
serve as MBNL1 binding motifs (Table S3) [9].
In human cerebellum, aberrant splicing was less apparent and
only splicing of SORBS1 exon 26 was altered significantly, while
similar splicing defects were shown in the hippocampus and
Figure 1. MBNL1 splicing targets in the mouse brain. RT-PCR analysis of wild-type (wt, n=3, 3–6 months of age) versus Mbnl1
DE3/DE3 (ko, n=3,
3–6months of age) brain splicing. (A) Representative PCR products. (B) Percent exon inclusion measured by phosphoimager analysis. Loss of MBNL1
expression results in reduced exon inclusion for Sorbs1 exon 25, Spag9 exon 31, Sorbs1 exon 6 and Dclk1 exon 19 in both the hippocampus (hp) and
cerebellum (cb). The inclusion of these exons is enhanced in the adult (P42) forebrain (fb) compared to the neonatal (P6) forebrain. Sorbs1 exon 25
splicing in the heart (ht) and Mprip splicing in the brain are included as positive and negative splicing controls. Both unpaired t-test and permutation
test were used for calculating p value (*p value,0.05, **p value,0.01). Averages and standard deviations were generated by unpaired t-test.
doi:10.1371/journal.pone.0033218.g001
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reason for this modest splicing alteration in the cerebellum of
human DM1 is that fetal splicing isoforms of some genes are
already dominantly expressed in human adult cerebellum and thus
there is no room for any detectable difference of fetal isoforms
between DM1 and control samples (e.g. CAMK2D in which fetal
d9 isoform is almost exclusively expressed in both disease control
and DM1 cerebellums relative to fetal brain (Figure 3E)). Another
possibility is that MBNL1 may not be as efficiently sequestered in
RNA foci in the DM1 cerebellar nucleus because the CTG repeat
expansion is much smaller in the cerebellum than in the temporal
cortex (Table 1). One alternative possibility is that MBNL1
contributes less significantly to the regulation of splicing in human
cerebellum. This possibility is unlikely, however, for the following
reasons. First, both the immunohistochemistry and western
blotting displayed similar expression of MBNL1 in different
regions of the brain (Figure S4, Material and Methods S1).
Second, since our RT-PCR demonstrated similar splicing defects
in Mbnl1 targeted exons in both the hippocampus and cerebellum
of Mbnl1 knockout mice (Figure 1), it seems that the contributions
of Mbnl1 to these regions are similar.
Compared with Mbnl1 knockout skeletal muscle, where 246
events achieved sepscore values of .0.3 [9], we observed far fewer
splicing events that exceeded this score. Some exons previously
reported to be mis-spliced in the DM1 brain were not observed in
the Mbnl1 knockout brain. In addition, the extent of splicing mis-
regulation in the mouse model was significantly less than observed
for DM1 (Figures 1, 2, 3). A possible explanation for these smaller
splicing changes in Mbnl1 knockout mouse brain is that there are
species differences of splicing regulation between mouse and
human. However, transgenic mouse brains carrying over 700
CTG repeat have been reported to display splicing abnormalities
of Mapt, Grin1, Mbnl1, and Mbnl2 [17]. These results suggest that
the contribution of MBNL1 to developmental splicing transitions
in the brain is less significant than in skeletal muscle or that the
cellular complexity of the brain masks a larger effect of MBNL1
loss on particular cell populations. Three genes encode MBNL
paralogs in mammals, MBNL1, MBNL2 and MBNL3, and all of the
encoded proteins have been demonstrated to colocalize with
nuclear foci in DM1 cells [18]. In reconstruction experiments
using transfected cells, each MBNL protein can regulate
alternative splicing of pre-mRNAs that are misregulated in DM1
[19]. As MBNL3 is expressed predominantly in the placenta [18],
the likely candidate which may play a more significant role in
alternative splicing in the brain is MBNL2. While human MBNL1
is expressed primarily in skeletal muscle and heart, MBNL2 is
expressed at a similar level in the majority of tissues [18]. Thus, the
contribution of MBNL2 to splicing changes may be relatively high
in brain in contrast to skeletal muscle. It has been reported that
Mbnl1 knockout mice demonstrate cognitive and behavioral
abnormalities and normal spatial learning and memory [20]. This
relatively mild phenotype may correlate with the modest splicing
alteration. Regarding exon 31 of Spag9 and exon 6 of Sorbs1,w e
found the significant difference between wild-type and Mbnl1
knockout, but not in human brains. This discrepancy may
contradict our hypothesis that the recruitment of MBNL1
contributes to the splicing defects in DM1 brains, but may be
explained by a difference of splicing regulation between mice and
human.
In vitro experiments suggested that a loss of MBNL1 or a gain
of CELF1 function could repress exon 3 inclusion but not exon 9
inclusion of Mapt, whereas CELF2 is a repressor of both exons
[21]. However, Mbnl1 knockout mice did not show any splicing
differences for these exons. This discrepancy about MBNL1
dependent regulation of the splicing of Mapt exon3 between in
vitro and mice experiments may also indicate that some redundant
factors function in this splicing regulation and loss of MBNL1
Figure 2. Spatial and temporal differences in the expression of
Camk2d. (A) Transcripts of Camk2d. (B) Representative PCR products.
Six spliced isoforms were detected by using primer pairs located in
exons 14a and 17. Right panel shows isoform switching from d9t od4
during the fetal (P1, P6) to adult (P42) transition in whole brain (wb),
forebrain (fb) and hindbrain (hb) whereas the d9i s o f o r mw a s
undetectable in adult hindbrain. Left panel shows a detectable increase
in the d9 isoform in Mbnl1
DE3/DE3 hippocampus (hp) compared with
wild-type sibs. However, no d9 isoform could be detected in the
cerebellum of either wild-type or Mbnl1 knockout mice. (C) The
percentage of Camk2d isoform d9t od1+4+9+3+2. Both unpaired t-test
and permutation test were used for calculating p value (n=3, *p
value,0.05). Averages and standard deviations were generated by
unpaired t-test.
doi:10.1371/journal.pone.0033218.g002
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DE3/DE3 brain are also observed in the human DM1 brain. We compared brain RNA from
normal control temporal cortex (control, tp, n=4), disease control temporal cortex (disease, tp, n=9), myotonic dystrophy type 1 temporal cortex
(DM1, tp, n=12), fetal control whole brain (fetal, wb, n=1), disease control cerebellum (disease, cb, n=4), and DM1 cerebellum (DM1, cb, n=5). (A)
Representative RT-PCR products detected with microchip electrophoretic separation using SV1210 software on the Hitachi SV1210 from exclusion
and inclusion of exon 26 of SORBS1 (upper), exon 19 of DCLK1 (middle), and exon 9 of MPRIP (bottom). (B) Graphical representation of RT-PCR analysis
depicting percentages of exon 26 inclusion of SORBS1 (upper), exon 19 inclusion of DCLK1 (middle), and exon 9 inclusion of MPRIP (bottom). (C)
Transcripts of CAMK2D. (D) Representative RT-PCR products from CAMK2D isoforms: d2(2exon14b2exon15), d9(2exon14b+exon15), and
d1(+exon14b+exon15) indicated by each arrow. (E) Graphical representation of RT-PCR analysis depicting percentages of d2 (upper), d9 (middle)
and d1 (bottom). Mann-Whitney U test was used for calculating the p value. Statistically significant differences (p,0.05) are indicated by an asterisk.
doi:10.1371/journal.pone.0033218.g003
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the brain.
SORBS1 was identified as a Cbl-associated protein likely to
participate in insulin signaling [22]. The targeted exon encodes the
nuclear localization sequence (NLS) [23], suggesting that the
protein without an NLS is increased in the DM1 brain and might
not be able to function as a nuclear protein. Among the four types
of CAMK2 isoforms, the CAMK2D is expressed predominantly in
the suprachiasmatic nucleus, substantia nigra, and striatum in the
brain. Since each spliced isoform of CAMK2D has been reported
to show a distinct distribution pattern [24,25], the increase in d9
might cause abnormal localization. Interestingly, CAMK2D has
been reported to play an essential role in PER1 expression, which
is possibly involved in light-induced phase shifts [26]. Although
excessive daytime sleepiness and dysregulation of REM sleep
occur frequently in patients with DM1, it was reported that the
pathophysiologic basis is distinct from narcolepsy, as patients with
DM1 do not have a consistent defect of hypocretin release or
receptor splicing [27]. Possibly, aberrant splicing of CAMK2D
might be associated with excessive daytime sleepiness in DM1.
DCLK1 is a microtubule-associated kinase that can undergo
autophosphorylation and regulate microtubule polymerization
[28]. The fetus specific C-terminal splicing variant (exon 19
exclusion), which is expressed more in DM1 adult temporal cortex,
showed enhanced autophosphorylation activity and has been
suggested a possible role in migrating neurons [29]. Therefore, the
increase in the fetal variant of DCLK1 in DM1 brain may cause
an abnormal neuronal migration. MPRIP was initially identified
as an 116 kDa protein that interacts with RhoA [30]. In neuronal
cells, MPRIP is essential for neurite outgrowth and may act as a
scaffold to target the myosin phosphatase complex to the actin
cytoskeleton [31]. Although the difference between splicing
isoforms has not been reported, aberrant splicing of this gene
could give rise to abnormal neurite outgrowth in DM1 brain.
In this study, we detected three novel splicing targets which
were mis-regulated in both Mbnl1 knockout mice and human
DM1, two only in Mbnl1 knockout mice, and one only in human
DM1 brains. Since the brain is a heterogeneous organ consisting
of many different cell types, splicing events may be regulated in a
region-specific manner. Our studies support this interpretation
with distinct variations in the splicing of developmentally-
regulated exons observed in the hippocampus and cerebellum.
Our results suggest that at least some of the aberrant splicing
events in the DM1 brain result from the sequestration of MBNL1
by CUG
exp RNAs. Additionally, it is also likely that other RNA-
associated proteins contribute to the aberrant splicing in DM1.
Thus, it will be important to investigate the splicing targets in
brain samples derived from other DM1 model mice, including
Celf1 transgenic, Celf2 transgenic and Mbnl2 knockout mice.
Materials and Methods
Ethics Statement
All experiments using mice were performed in accordance with
the guidelines of the University of Florida. The protocol was
approved by the University of Florida Institutional Animal Care
and Use Committee (Permit Number: #200903677). All exper-
iments using human samples were approved by the Ethics
Committee of Hyogo College of Medicine (Permit number: 93)
and written informed consent for specimen use for research was
obtained from all patients.
Splicing Microarray Detection
RNA samples from the brain of individual 12–14-week-old male
mice from the wild-type and Mbnl1
DE3/DE3 lines (n=4 for each
group) were compared. To identify MBNL1-dependent splicing
events, RNA from Mbnl1
DE3/DE3 mice was compared to wild-type
mice in the C57BL/6J (N10) background. RNA samples were
processed for cDNA synthesis and hybridization to Affymetrix ‘‘A-
chip’’ oligonucleotide microarrays as follows. Total RNA was
primed with random hexamers and reverse transcribed. After the
reaction was completed, RNA was removed from the reaction by
alkaline hydrolysis and the cDNA was purified using Qiagen PCR
Quick Purification Kit. A typical reaction started with 5 mg of total
RNA usually yielded ,3 mg of cDNA. The cDNA was then
Table 1. Human samples analysed.
Patient no/sex Age disaese Sources
CTG repeats in
brain samples
C1/M 23
anormal temporal cortex
C2/M 22
anormal temporal cortex
C3/M 26
anormal temporal cortex
C4/F 78
bnormal temporal cortex
D1/F 69 PD temporal cortex
D2/F 84 MSA-C temporal cortex
D3/F 80 ALS temporal cortex
D4/M 53 ALS temporal cortex
cerebellum
D5/F 81 ALS temporal cortex
cerebellum
D6/M 70 ALS temporal cortex
D7/F 75 ALS temporal cortex
D8/F 61 ALS temporal cortex
cerebellum
D9/M 70 ALS temporal cortex
cerebellum
DM1/M 58 DM1 temporal cortex 3000–6000
DM2/M 69 DM1 temporal cortex 3000–6000
DM3/M 50 DM1 temporal cortex 2000–6000
DM4/F 56 DM1 temporal cortex 3000–5000
cerebellum 400
DM5/M 63 DM1 temporal cortex 1200–3000
DM6/M 59 DM1 temporal cortex 3000–9000
DM7/F 58 DM1 temporal cortex 3000–6000
cerebellum 2200–3000
DM8/F 58 DM1 temporal cortex 2000–8000
DM9/F 58 DM1 temporal cortex 2200–6500
cerebellum 300
DM10/F 66 DM1 temporal cortex 1900–3300
cerebellum 150
DM11/M 64 DM1 temporal cortex 2400–5200
DM12/F 73 DM1 temporal cortex 1900–4800
cerebellum 200
F1/F 21w
cfetal whole brain
afrom Biochain,
bfrom Ambion,
cfrom Stratagene, PD; Parkinson’s disease; MSA-C; multiple system atrophy with
predominant cerebellar ataxia; ALS: amyotrophic lateral sclerosis.
doi:10.1371/journal.pone.0033218.t001
Novel Splicing Defects in Mbnl1 KO and DM1 Brain
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33218fragmented using DNase I in an empirically controlled reaction
that yields DNA fragments of 50–200 bases. This fragmented
cDNA was then end labeled using terminal deoxynucleotidyl
transferase and ‘‘DNA-Labeling-Reagent-1a (DLR-1a)’’, which is
a biotinylated dideoxynucleoside triphosphate. Labeled cDNA was
hybridized to arrays in standard Affymetrix hybridization buffer
for 16 hrs at 50uC. Arrays were washed, processed with anti-biotin
antibodies and streptavidin-phycoerythrin according to the
standard Affymetrix protocol.
Microarray Data Analysis
Analysis was done according to Sugnet et al. [32], who calculate
a ‘‘separation score’’ that measures the relative change in ratio of
alternative splicing events. The equation for sepscore is:
Separation score sepscore ðÞ ~
Log2 mut skip=include ðÞ =wt skip=include ðÞ ½ 
For each replicate set (each tissue from Mbnl1
DE3/DE3 and wild
type), we estimated the log2 ratio of skipping to inclusion using
robust least squares analysis. We evaluated sepscore significance
by permuting the assignments of data points to replicate sets,
calculating the separation score for the permuted data, and
estimating the likelihood that the observed data came from the
permuted distribution. The microarray data have been deposited
in NCBI’s Gene Expression Omnibus and are accessible through
GEO series accession number GSE28640 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE28640). All data is MIAME
compliant and the raw data has been deposited in a MIAME
compliant database (GEO), as detailed on the MGED Society
website (http://www.mged.org/Workgroups/MIAME/miame.
html).
Target validation by RT-PCR for model mice
The sequences of primers used for RT–PCR assays of splicing
in mouse and human brain RNA are listed in (Tables S1 and S2).
To test mouse MBNL1 potential splicing targets identified by
splicing microarrays, we harvested hippocampal, temporal cortex
and cerebellar tissues from Mbnl1
+/+ (n=3) and Mbnl1
DE3/DE3
(n=3) mice (C57BL/6J background) ranging from 3–6 months of
age. RNA was isolated using TRI Reagent (Sigma) and cDNA
generated using 5 mg of RNA, oligo (dT)20 (Invitrogen) and
SuperScript III (Invitrogen) followed by digestion with 0.2 units/ml
RNase H (Invitrogen) at 37uC for 20 min. Splicing targets with
predicted alternately spliced cassettes were selected from micro-
array list and 5 ng of cDNA was PCR-amplified for 28 cycles
(95uC for 30 sec, 55uC for 30 sec, 72uC for 30 sec) by using
forward and reverse primers located in the flanking exons. Each
PCR reaction was spiked with 2.5 mCi of [a
32P]-dCTP (Perki-
nElmer Life Sciences). PCR products were resolved on 10% non-
denaturing polyacrylamide gels followed by autoradiography using
Kodak BioMax MS film (PerkinElmer Life Sciences). Exon
inclusion was measured using a Typhoon 9200 imager and
ImageQuant TL software (GE Healthcare).
RT-PCR and Southern blot analysis for human brain
samples
Human temporal cortex and cerebellar tissues (n=21) at
autopsy were analyzed (Table 1). RNA was extracted from each
sample by the ISOGEN procedure (Nippon Gene). The RNAs
used as normal controls were purchased commercially as follows:
human adult temporal cortex (3 male, 1female, 3 samples from
Biochain, 1 sample from Ambion) and 1 sample of human fetal
whole brain (Stratagene) (Table 1). The quality of RNA and the
PCR product were analyzed by capillary electrophoresis using a
Hitachi SV 1210 on a microchip (Hitachi Electronics Co., Tokyo,
Japan) [33]. We used the samples which meet the criteria that the
ratio of 28S/18S rRNA peaks was .0.8. The CTG trinucleotide
repeat expansion sizes of human brain samples were determined
by Southern blot analysis of genomic DNAs from each brain
region tissue of DM1 as described previously [34]. cDNA was
synthesized using the same method as for mouse samples except 1–
3 mg of RNA and random hexamers were used. cDNA equivalent
to 20 ng RNA was PCR-amplified for initial denaturation at 94uC
for 10 min and 35 cycles (94uC for 30 sec, 55uC for 30 sec, 72uC
for 30 sec) by using forward and reverse primers located in the
exons adjacent to the human exons orthologous to mouse exons
predicted by the microarray data (Table S2). We determined the
percentage of each peak by dividing each signal by the total signal.
Statistical analysis
Differences for the levels of exon inclusion for age-matched
genetically homogeneous mice were analyzed by unpaired t- and
permutation tests. The data for human samples were analyzed
using the nonparametric Mann-Whitney U test because the
backgrounds such as age and CTG repeat number of each sample
are regarded inhomogeneous and the data for these samples were
not always normally distributed.
Supporting Information
Figure S1 Sorbs1 exon 25 inclusion is decreased and
Camk2d d9 is increased to similar extent in the
hippocampus (hp) and temporal cortex (tp) of
Mbnl1
DE3/DE3 (ko) mice compared with wild type (wt)
mice.
(TIF)
Figure S2 Comparison between the degree of aberrant
splicing and CTG repeat number in DM1 brain. There
was no significant correlation between each shortest, median and
longest CTG repeat number, and percent inclusion of each of the
exons which are mis-regulated. (A) Temporal tissues. (B)
Cerebellar tissues. Spearman rank correlation coefficient was used
for the analysis of correlation.
(TIF)
Figure S3 Some splicing defects which have been
reported in DM1 brain were not reproduced in Mbnl1
knockout brain. (A) Four splicing exons are mis-regulated in
our human DM1 temporal cortex (exon4 of GRIN1, exons 3 and
12 of MAPT, and exon9 of APP). Mann-Whitney U test was used
for calculating the p value. Statistically significant differences
(p,0.05) are indicated by an asterisk. (B) These exons are normally
spliced in the hippocampus (hp) of Mbnl1 knockout mice.
(TIF)
Figure S4 MBNL1 distribution and expression in re-
gions of mouse brain. (A) Immnunohistochemistry with anti-
MBNL1 antibody shows that MBNL1 is ubiquitously expressed in
the frontal cortex (top), hippocampus (middle), and cerebellum
(bottom) sections from wild-type (wt, right) but not in those from
Mbnl1 knockout (ko, left). (B) Western blot analysis shows a similar
expression of MBNL1 in the cerebellum, temporal cortex, and
hippocampus of a wild-type mouse. (Materials and Methods S1).
(TIF)
Materials and Methods S1 Supplementary Materials
and Methods for Muscleblind-Like 1 Knockout Mice
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(DOC)
Table S1 Separation score and primers for RT-PCR of
mouse brain.
(DOC)
Table S2 Primers for RT-PCR of human brain.
(DOC)
Table S3 YGCY motif searching list with sequences exons
aberrantly regulated in brains of Mbnl1 knockout mice
and DM1 patients. YGCY motifs are indicated by capitals.
(DOC)
Acknowledgments
The authors would like to acknowledge the Research Resource Network
Japan for supplying human brain tissue samples.
Author Contributions
Conceived and designed the experiments: KS K-YL HF KJ MA MSS TK.
Performed the experiments: KS K-YL MN YT HF KJ HD MSS. Analyzed
the data: KS MN YT MPT KJ HY HD MA MSS TK. Contributed
reagents/materials/analysis tools: HF KJ. Wrote the paper: KS K-YL MN
YT MPT HY MA MSS TK.
References
1. Meola G, Sansone V (2007) Cerebral involvement in myotonic dystrophies.
Muscle Nerve 36: 294–306.
2. Ono S, Kanda F, Takahashi K, Fukuoka Y, Jinnai K, et al. (1996) Neuronal loss
in the medullary reticular formation in myotonic dystrophy: a clinicopatholog-
ical study. Neurology 46: 228–231.
3. Ono S, Inoue K, Mannen T, Mitake S, Shirai T, et al. (1989) Intracytoplasmic
inclusion bodies of the thalamus and the substantia nigra, and Marinesco bodies
in myotonic dystrophy: a quantitative morphological study. Acta neuropathol
77: 350–356.
4. Vermersch P, Sergeant N, Ruchoux MM, Hofmann-Radvanyi H, Wattez A,
et al. (1996) Specific tau variants in the brains of patients with myotonic
dystrophy. Neurology 47: 711–717.
5. Harper PS (2001) Myotonic Dystrophy 3rd ed. W. B. Saunders.
6. Sicot G, Gourdon G, Gomes-Pereira M (2011) Myotonic dystrophy, when
simple repeats reveal complex pathogenic entities: new findings and future
challenges. Hum Mol Genet 20: R116–123.
7. Mankodi A, Logigian E, Callahan L, McClain C, White R, et al. (2000)
Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat.
Science 289: 1769–1773.
8. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, et al. (2003)
A muscleblind knockout model for myotonic dystrophy. Science 302:
1978–1980.
9. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA, et al. (2010) Aberrant
alternative splicing and extracellular matrix gene expression in mouse models of
myotonic dystrophy. Nat Struct Mol Biol 17: 187–193.
10. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA (2004) Myotonic
dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of
muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol
Genet 13: 3079–3088.
11. Dhaenens CM, Schraen-Maschke S, Tran H, Vingtdeux V, Ghanem D, et al.
(2008) Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in
the DM1 brain: Two individual consequences of CUG trinucleotide repeats.
Exp Neurol 210: 467–478.
12. Leroy O, Wang J, Maurage CA, Parent M, Cooper T, et al. (2006) Brain-specific
change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1.
Biochim Biophys Acta 1762: 460–467.
13. Sergeant N, Sablonniere B, Schraen-Maschke S, Ghestem A, Maurage CA,
et al. (2001) Dysregulation of human brain microtubule-associated tau mRNA
maturation in myotonic dystrophy type 1. Hum Mol Genet 10: 2143–2155.
14. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, et al. (2008) A postnatal
switch of CELF and MBNL proteins reprograms alternative splicing in the
developing heart. Proc Natl Acad Sci U S A 105: 20333–20338.
15. Donai H, Murakami T, Amano T, Sogawa Y, Yamauchi T (2000) Induction
and alternative splicing of delta isoform of Ca(2+)/calmodulin-dependent
protein kinase II during neural differentiation of P19 embryonal carcinoma cells
and during brain development. Brain Res Mol Brain Res 85: 189–199.
16. Lopez Castel A, Nakamori M, Tome S, Chitayat D, Gourdon G, et al. (2011)
Expanded CTG repeat demarcates a boundary for abnormal CpG methylation
in myotonic dystrophy patient tissues. Hum Mol Genet 20: 1–15.
17. Gomes-Pereira M, Foiry L, Nicole A, Huguet A, Junien C, et al. (2007) CTG
trinucleotide repeat ‘‘big jumps’’: large expansions, small mice. PLoS Genet 3:
e52.
18. Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, et al. (2002)
Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci
of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet 11:
805–814.
19. Ho TH, Charlet BN, Poulos MG, Singh G, Swanson MS, et al. (2004)
Muscleblind proteins regulate alternative splicing. EMBO J 23: 3103–3112.
20. Matynia A, Ng CH, Dansithong W, Chiang A, Silva AJ, et al. (2010)
Muscleblind1, but not Dmpk or Six5, contributes to a complex phenotype of
muscular and motivational deficits in mouse models of myotonic dystrophy.
PLoS One 5: e9857.
21. Dhaenens CM, Tran H, Frandemiche ML, Carpentier C, Schraen-Maschke S,
et al. (2011) Mis-splicing of Tau exon 10 in myotonic dystrophy type I is
reproduced by overexpression of CELF2 but not by MBNL1 silencing. Biochim
Biophys Acta 1812: 732–742.
22. Ribon V, Printen JA, Hoffman NG, Kay BK, Saltiel AR (1998) A novel,
multifuntional c-Cbl binding protein in insulin receptor signaling in 3T3-L1
adipocytes. Mol Cell Biol 18: 872–879.
23. Lebre AS, Jamot L, Takahashi J, Spassky N, Leprince C, et al. (2001) Ataxin-7
interacts with a Cbl-associated protein that it recruits into neuronal intranuclear
inclusions. Hum Mol Genet 10: 1201–1213.
24. Xu X, Yang D, Ding JH, Wang W, Chu PH, et al. (2005) ASF/SF2-regulated
CaMKIIdelta alternative splicing temporally reprograms excitation-contraction
coupling in cardiac muscle. Cell 120: 59–72.
25. Takeuchi Y, Nomura K, Fukunaga K (2004) Differential subcellular distribution
of Ca2+/calmodulin-dependent protein kinase II isoforms in the striatum and
NG108-15 cells. J Neurosci Res 75: 480–490.
26. Nomura K, Takeuchi Y, Yamaguchi S, Okamura H, Fukunaga K (2003)
Involvement of calcium/calmodulin-dependent protein kinase II in the
induction of mPer1. J Neurosci Res 72: 384–392.
27. Ciafaloni E, Mignot E, Sansone V, Hilbert JE, Lin L, et al. (2008) The
hypocretin neurotransmission system in myotonic dystrophy type 1. Neurology
70: 226–230.
28. Lin PT, Gleeson JG, Corbo JC, Flanagan L, Walsh CA (2000) DCAMKL1
encodes a protein kinase with homology to doublecortin that regulates
microtubule polymerization. J Neurosci 20: 9152–9161.
29. Burgess HA, Reiner O (2002) Alternative splice variants of doublecortin-like
kinase are differentially expressed and have different kinase activities. J Biol
Chem 277: 17696–17705.
30. Gebbink MF, Kranenburg O, Poland M, van Horck FP, Houssa B, et al. (1997)
Identification of a novel, putative Rho-specific GDP/GTP exchange factor and
a RhoA-binding protein: control of neuronal morphology. J Cell Biol 137:
1603–1613.
31. Mulder J, Ariaens A, van den Boomen D, Moolenaar WH (2004) p116Rip
targets myosin phosphatase to the actin cytoskeleton and is essential for RhoA/
ROCK-regulated neuritogenesis. Mol Biol Cell 15: 5516–5527.
32. Sugnet CW, Srinivasan K, Clark TA, O’Brien G, Cline MS, et al. (2006)
Unusual intron conservation near tissue-regulated exons found by splicing
microarrays. PLoS Comput Biol 2: e4.
33. Kataoka M, Inoue S, Kajimoto K, Sinohara Y, Baba Y (2004) Usefulness of
microchip electrophoresis for reliable analyses of nonstandard DNA samples and
subsequent on-chip enzymatic digestion. Eur J Biochem 271: 2241–2247.
34. The International Myotonic Dystrophy Consortium (IDMC). (2000) New
nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1).
Neurology 54: 1218–1221.
Novel Splicing Defects in Mbnl1 KO and DM1 Brain
PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33218